Zacks Research Lowers Earnings Estimates for Globus Medical

Globus Medical, Inc. (NYSE:GMED - Free Report) - Research analysts at Zacks Research cut their Q2 2025 earnings estimates for Globus Medical in a research report issued to clients and investors on Monday, June 30th. Zacks Research analyst R. Department now anticipates that the medical device company will earn $0.78 per share for the quarter, down from their previous estimate of $0.79. The consensus estimate for Globus Medical's current full-year earnings is $3.44 per share. Zacks Research also issued estimates for Globus Medical's FY2025 earnings at $3.16 EPS, Q4 2026 earnings at $0.94 EPS and FY2027 earnings at $4.17 EPS.

Globus Medical (NYSE:GMED - Get Free Report) last announced its earnings results on Thursday, May 8th. The medical device company reported $0.68 EPS for the quarter, missing the consensus estimate of $0.74 by ($0.06). The firm had revenue of $598.12 million for the quarter, compared to the consensus estimate of $629.74 million. Globus Medical had a return on equity of 10.52% and a net margin of 7.39%. Globus Medical's revenue for the quarter was down 1.4% on a year-over-year basis. During the same period in the previous year, the firm earned $0.72 EPS.

Other analysts also recently issued reports about the stock. Needham & Company LLC reiterated a "hold" rating on shares of Globus Medical in a report on Tuesday, March 18th. Truist Financial dropped their price target on Globus Medical from $80.00 to $68.00 and set a "hold" rating on the stock in a report on Monday, May 12th. Piper Sandler decreased their target price on Globus Medical from $100.00 to $80.00 and set an "overweight" rating on the stock in a report on Friday, May 9th. Barclays reaffirmed an "overweight" rating on shares of Globus Medical in a report on Tuesday, June 10th. Finally, JMP Securities reissued a "market perform" rating on shares of Globus Medical in a research note on Tuesday, May 27th. Five investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $94.00.

Globus Medical Stock Up 0.6%

Globus Medical stock traded up $0.33 during midday trading on Tuesday, hitting $60.53. The company's stock had a trading volume of 1,746,085 shares, compared to its average volume of 1,127,027. Globus Medical has a 12 month low of $54.48 and a 12 month high of $94.93. The company has a market capitalization of $8.19 billion, a PE ratio of 45.17, a price-to-earnings-growth ratio of 1.75 and a beta of 1.19. The stock's 50-day moving average price is $62.16 and its 200-day moving average price is $74.25.

Globus Medical announced that its board has initiated a stock buyback program on Thursday, May 15th that permits the company to buyback $500.00 million in shares. This buyback authorization permits the medical device company to repurchase up to 6.3% of its shares through open market purchases. Shares buyback programs are often an indication that the company's management believes its shares are undervalued.

Institutional Investors Weigh In On Globus Medical

A number of institutional investors have recently modified their holdings of the stock. Invesco Ltd. raised its position in Globus Medical by 331.9% during the first quarter. Invesco Ltd. now owns 2,021,156 shares of the medical device company's stock valued at $147,949,000 after acquiring an additional 1,553,154 shares in the last quarter. Norges Bank acquired a new position in shares of Globus Medical during the 4th quarter worth $117,102,000. RTW Investments LP bought a new position in shares of Globus Medical during the 4th quarter valued at $80,394,000. Iron Triangle Partners LP bought a new stake in Globus Medical in the fourth quarter worth $69,808,000. Finally, Polar Capital Holdings Plc acquired a new position in Globus Medical during the fourth quarter worth $63,762,000. Institutional investors and hedge funds own 95.16% of the company's stock.

About Globus Medical

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.